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Abstract
The sensitivity of massively-parallel sequencing has confirmed that most cancers are oligoclonal, with subpopulations of
neoplastic cells harboring distinct mutations. A fine resolution view of this clonal architecture provides insight into tumor
heterogeneity, evolution, and treatment response, all of which may have clinical implications. Single tumor analysis already
contributes to understanding these phenomena. However, cryptic subclones are frequently revealed by additional patient
samples (e.g., collected at relapse or following treatment), indicating that accurately characterizing a tumor requires
analyzing multiple samples from the same patient. To address this need, we present SciClone, a computational method that
identifies the number and genetic composition of subclones by analyzing the variant allele frequencies of somatic
mutations. We use it to detect subclones in acute myeloid leukemia and breast cancer samples that, though present at
disease onset, are not evident from a single primary tumor sample. By doing so, we can track tumor evolution and identify
the spatial origins of cells resisting therapy.
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heterogeneity of a given sample. The emerging picture from these
studies, across a diversity of solid [6,8,9,11,13,16] and hematological [4,5,7,10,12,14,15,17,22] disorders, is that tumors are both
spatially [9,13,16] and temporally [4–17] heterogeneous and are
frequently comprised of a single founding clone and several
subclones.
Increasing evidence suggests that intra-tumor heterogeneity and
clonal architecture have clinical implications [3,23,24] and
contribute to therapy resistance [25]. Several studies have linked
the presence of subclones to poor clinical outcome, as in chronic
lymphocytic leukemia (CLL) [10], or to increased risk of
progression to malignancy, as in Barrett’s esophagus [26] and
multiple myeloma (MM) [17]. Subclonal mutations can drive
resistance as well, as shown in EGFR-mutant non-small cell lung
cancers [27,28]. Studies in chronic myeloid leukemia have also
demonstrated that drug-resistant subclones may harbor aggressive
mutations that are restrained by more fit, but indolent clones [2,3].
In these cases, therapeutic application of imatinib leads to
competitive release of BCR-ABL mutant subclones, which renders
the therapy ineffective [3,29]. Thus, designing effective second line
therapies requires a deep understanding of both a cancer’s

Introduction
Cancer is a disease largely driven by accumulated somatic
mutations. Many of these are clonal mutations and occur in the
founding cell to initiate disease. These become uniformly present
in the tumor by propagating to that cell’s progeny during clonal
expansion. Others are subclonal events, which occur in an existing
neoplastic cell and are then passed on only to the subpopulation of
cells derived from it. The result of this accumulation of mutations
is that tumors are composed of a heterogeneous mixture of cells.
These subpopulations compete and evolve [1–3], and the
mutations ‘‘captured’’ [4] in subsets of cells during this evolution
serve as a genetic signature of the resulting (sub)clones.
Recently, high resolution glimpses of this clonal heterogeneity
have been provided by next-generation sequencing [4–14], SNP
array [6,10,13,15], and array comparative genomic hybridization
[16,17] platforms. Single-cell sequencing [16,18–20] may eventually address this heterogeneity directly without the confounding
effects of mixing cell types, but technical challenges, such as allele
dropout [21], remain. There are also pragmatic concerns about
the large number of cells that must be sequenced to establish the
PLOS Computational Biology | www.ploscompbiol.org
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To address these needs, we introduce SciClone, a method for
estimating the number and content of subclones across one or
many samples. It focuses primarily on variants in copy-number
neutral, loss of heterozygosity (LOH)-free portions of the genome,
which allows for the highest-confidence quantification of variant
allele frequencies (VAF) and inference of clonality. As with other
tools [6,11,22,30], regions of CNA and LOH are provided as
inputs after having been inferred from whole-exome sequencing
(WES, e.g., via ASCAT [22,34], cn.MOPS [35–37], or VarScan 2
[38]), whole-genome sequencing (WGS, e.g., via HMMcopy/
APOLLOH [11,39] or VarScan 2 [38]), or SNP arrays (e.g., via
ASCAT [6,22,34]). SNVs of sufficient depth are provided by WES
or first discovered by WGS and subsequently deeply sequenced in
a targeted fashion. The approach is not limited to SNVs, but is
amenable to any event that can be described as a frequency. In
particular, we demonstrate the integration of copy number events
and discuss how copy-altered VAFs could be accommodated.
Computational efficiency is achieved by clustering the VAFs
using a variational Bayesian mixture model [40] (VBMM), which
differs substantially from the Dirichlet process models previously
used to infer subclones [6,10,11,22,30,31]. VBMMs similarly
automatically infer the number of clusters and provide a
probabilistic interpretation of clustering, but their deterministic
nature allows them to scale to high dimension, where they enjoy
efficiency advantages [40] over stochastic MCMC techniques
employed by existing clonality detection methods [6,10,11,
22,30,31]. Further, the variational Bayesian approach provides a
computational termination condition more straightforward than
monitoring techniques [41] required of MCMC. Though VBMMs
are heuristic, and their approximations occasionally result in suboptimal solutions [42], we demonstrate their effectiveness here
through simulation and application to several real tumor data sets.
In particular, SciClone advances our preliminary [14] variational
Bayesian beta mixture modeling approach for clustering VAFs in a
single sample by: (1) applying the standard technique of factorizing
the density over samples [43,44] to extend applicability to an
arbitrary number of samples, (2) replacing our previous ad hoc
notion of cluster overlap with a quantitative measure [45,46], (3)
leveraging the probabilistic nature of VBMMs to quantify a
variant’s likelihood of belonging to a cluster via a p-value, and (4)
offering alternative binomial and Gaussian mixture models.
We demonstrate SciClone by inferring low-frequency subclones
from a single MM sample and by quantitatively assessing the
clonality of driver mutations in (potentially noisy) WES-derived
data. We extend this approach to accommodate multiple samples
and apply it to track clonal evolution of an acute myeloid leukemia
(AML) tumor to relapse in response to therapy. As a further
example of SciClone’s scalability and utility in correlating
mutations across samples, we examine spatial heterogeneity and
aromatase-inhibitor resistance within three samples from a single
breast cancer patient. In both the AML and breast cancer data
sets, our analysis reveals subclones present in the primary tumor
but not discernible from a single primary tumor sample. This
reinforces the necessity of analyzing multiple patient-derived
tumor samples to elucidate the full complexity of a cancer’s
heterogeneity.
The SciClone package is available at http://github.com/
genome/sciclone.

Author Summary
Sequencing the genomic DNA of cancers has revealed that
tumors are not homogeneous. As a tumor grows, new
mutations accumulate in individual cells, and as these cells
replicate, the mutations are passed on to their offspring,
which comprise only a portion of the tumor when it is
sampled. We present a method for identifying the fraction
of cells containing specific mutations, clustering them into
subclonal populations, and tracking the changes in these
subclones. This allows us to follow the clonal evolution of
cancers as they respond to chemotherapy or develop
therapy resistance, processes which may radically alter the
subclonal composition of a tumor. It also gives us insight
into the spatial organization of tumors, and we show that
multiple biopsies from a single breast cancer may harbor
different subclones that respond differently to treatment.
Finally, we show that sequencing multiple samples from a
patient’s tumor is often critical, as it reveals cryptic
subclones that cannot be discerned from only one sample.
This is the first tool that can efficiently leverage multiple
samples to identify these as distinct subpopulations of
cells, thus contributing to understanding the biology of
the tumor and influencing clinical decisions about therapy.

underlying mutations and how it’s clonal structure evolves in
response to treatment.
Existing methods [6,10,11,22,30–32] have been useful for
inferring clonal architecture and its consequences, e.g., that
putative driver mutations in SF3B1 and TP53 in CLL [10] and in
PIK3CA and PTEN in triple-negative breast cancer [11] may
arise during late-emerging, subclonal diversification [6] rather
than as founding lesions. Recent results suggest that accurately
describing the subclonal composition and evolution of tumors
requires sampling cancer cells across multiple time points or
spatially-distinct regions [3,23,25]. Current studies of distant
metastases and of spatial heterogeneity are collecting as many as
six to twenty samples [9,13,16,18]. The scale of these ambitious
studies will challenge existing methods. For example, histogrambased approaches to representing clonal markers [10,31] are
attractive in avoiding model assumptions in low dimensions (i.e.,
with few samples), but with many samples will suffer from
exponential computational complexity. Several approaches
[6,10,11,22,30,31] leverage Markov chain Monte Carlo (MCMC)
techniques, but these, too, are computationally demanding and
rely on assumptions about chain convergence.
Most existing methods [6,10,22,31] inferring clonality from
copy number alterations (CNAs) avoid additional computational
overhead by making the simplifying assumption that the tumor
sample is ‘‘monogenomic’’ [31] and does not harbor subclonal
copy-number events. Contrary to their assumptions, these
methods have detected such subclonal events in CLL [10], though
without being able to correct for them. Similar subclonal events
have been detected in MM (Ref. [33] and B.S.W., R.V., and
M.H.T, data not shown). These methods introduce uncertainty,
through the probabilistic inference of allele-specific copy numbers,
and error, by ignoring subclonal CNAs. A recent approach [32]
does generalize to subclonal CNAs, but also suffers from
computational inefficiencies when extended beyond the simple
case of clonal CNAs. A method which could avoid the uncertainty
of deconvolving subclonal CNAs and operated with significantly
lower computational demands would benefit studies aiming to
understand the evolution of cancer.
PLOS Computational Biology | www.ploscompbiol.org
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Mixture modeling objectively identifies subclones
Many tumors are highly heterogeneous and visualizations of
somatic VAFs reveal high-density aggregations that correspond to
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mutations in these (and other) copy number altered regions are
shifted in a predictable pattern, with a doubling of VAFs in regions of
single-copy deletion where only the variant allele remains (Fig. 1b). In
regions of single-copy amplification, mutations group near the
expected frequency of * 31% where the wild-type allele is amplified
(i.e., ,1 variant allele/3 total alleles) or * 62% when the mutant
allele is amplified (i.e., * 2 variant alleles/3 total alleles; Fig. 1d). A
more careful calculation that incorporates the tumor purity
r tumor ~ 0:922 gives an expected frequency of the mutant-amplified
cluster, 100 | 2r tumor =½ 3r tumor z 2ð 1 { r tumor Þ  & 62% ,
very close to the observed frequency of 63%. The same holds for the
wild-type-amplified cluster.
In this patient, these wild-type amplified SNVs occur at similar
VAFs to subclonal events that are copy number neutral (red circles
in Fig 1c). Disambiguating the two would require inference of

specific subpopulations of cells (Fig. 1). To test our ability to detect
and segregate these clusters, we used 2,018 validated, deepsequenced (median depth 188x), genome-wide somatic SNVs from
a primary MM tumor (M.H.T., et al., in preparation). These
formed a high density region near 50% VAF, as expected of
heterozygous SNVs in the founding clone of a nearly pure tumor
sample (Figs. 1a and c). The actual average VAF of this founding
clone is slightly less (46.1%), reflecting a small amount of normal
cell admixture and a tumor purity r tumor of 0.922. Lower VAFs
correspond to subclone-specific mutations that arose later in the
tumor’s expansion; a cluster of such VAFs thus represents a
subclonal population, whose cells contain all of the founding clone
mutations, as well as these subclonal mutations.
This tumor is hyperdiploid with characteristic trisomies of
chromosomes 3, 5, 7, 9, 11, 15, 19, and 21. Founding clone

Figure 1. Inferring subclonal architecture objectively in multiple myeloma. (a) Kernel density plots of VAFs across regions with copy
number one, two, or three, posterior predictive densities summed over all clusters for copy number neutral variants, and posterior predictive
densities for each cluster/component. (b-d) VAFs plotted versus read depth for each of the three copy number regions. (c) Three mutation clusters
(green, dark orange, and blue) were detected using variants from copy number neutral segments. (d) Two clusters centered at VAF 31% and 62%
were detected from variants in copy number three segments; they likely result from single-copy amplification of the wild-type or the mutant allele of
mutations in the founding clone.
doi:10.1371/journal.pcbi.1003665.g001
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allele- (and subclone-) specific copy number profiles, with its
attendant uncertainty. To confirm that the two cases are in fact
distinct and not an artifact of inaccurate copy number calls, we
verified that none of the subclonal event VAFs in putative copynumber neutral regions reside instead on trisomic chromosomes.
Further, they are not restricted to one or a few chromosomes,
whose amplification or deletion might not have been detected,
thus leading to apparent subclonal events.
To obtain a more objective view of this sample’s clonal
architecture, we identified low-frequency subclones by clustering
the VAFs from copy number neutral, LOH-free, non-repetitive
regions of the genome using SciClone, which uses an approach
based on variational Bayesian beta mixture modeling [43,44,47].
The method automatically infers the optimal number of clusters,
based on an initial overestimation of their expected number (ten,
unless specified otherwise). In this MM sample, SciClone detected
three clusters (Fig. 1): the first with average VAF of 46.1%, and
two lower-frequency clusters with average VAFs of 32.0% and
11.9% (Fig. 1). Each cluster is represented by a posterior
predictive density (see Materials and Methods), which provides
the probability of a VAF given the observed data (and subsequent
model fit). These densities probabilistically define boundaries
between clusters, including the visually ambiguous separation
between the highest-frequency cluster and the cluster with average
VAF of 32.0%.
As a comparison for our results, we applied an MCMC method,
PyClone [11,30], to the same variants in copy-number neutral,
LOH-free regions. PyClone recapitulated the presence of the
minor clusters, though with increased computational demands
(Table S1). We tested PyClone’s ability to integrate copy-number
altered SNVs expected to be in the founding clone and found that
it often assigned these sites to independent clusters.
As a second point of comparison, we applied THetA [32], a
method that infers clonal architecture based on copy number
events alone. For reasons of computational complexity, we
applied it to a limited number of segments with representative
copy number states. THetA detected clonal amplifications that
occurred in 89.8% of the cells (44.9% VAF) and a subclonal
deletion that occurred in 54.1% of the cells (27.0% VAF). We
integrated these data and SciClone clustering of all CNA and
SNV VAFs revealed that the THetA-inferred CNA VAFs support
the presence of subclones originally inferred from SNVs alone
(Fig. S1).
In some samples, ordering of subclonal VAFs may reveal the
clonal phylogeny of the tumor [48]. However, in this sample, the
data are insufficient to distinguish between a branched phylogeny,
in which the two subclones arose from independent cells within the
founding clone, and a linear phylogeny, where the lower VAF
subclone is descended from the higher VAF subclone. The latter
case implies that all mutations in the higher VAF subclone are also
present in the lower VAF subclone, as are all founding clone
mutations.

endometrioid carcinoma [50] cancer samples from The Cancer
Genome Atlas (TCGA) project. To obtain a sufficient number of
variants, we relaxed the minimum depth of coverage requirement
to 50x, resulting in 29 copy-number neutral variants from the
breast sample and 53 from the endometrial sample. The breast
tumor has a high-VAF cluster corresponding to its founding clone
as well as a subclonal cluster, with most variants occurring in the
latter (Fig. 2a). The endometrial sample is more complex, with
both a high-VAF cluster and three tightly-grouped and poorlyseparated subclonal clusters (Fig. 2b).
Drawing inferences about mutation clonality (e.g., assessing
whether mutations generally occur in the founding clone and
hence are likely to be early, disease-initiating events [14] or
attempting to correlate subclonal mutations with clinical outcome
[10]) requires accurately and confidently assigning individual
VAFs to clusters. Our variational Bayesian approach does so via
‘‘fuzzy’’ cluster assignments, which describe the (conditional,
posterior) probability that a VAF belongs to a particular cluster
(given that it belongs to one of them). In particular, the likely
driver PIK3CA mutations in the endometrial sample are assigned
confidently to the highest-frequency cluster one, with probabilities
of 93.1% for the lower VAF variant and 97.1% for the higher. In
contrast, the potential driver ATM mutation is nearly as likely to
belong to cluster one (42.1% probability) as to the lower VAF
cluster two (57.8% probability) to which it was ‘‘assigned’’ (i.e.,
that which maximized its posterior probability). Given the
relatively few SNVs, this ambiguous assignment indicates that
the data are insufficient to accurately define the clonal structure
and that the separation between cluster one and cluster two may
be an artifact of sparse data. This uncertainty might be resolved by
increased depth of sequencing or by additional clonal markers
(e.g., as discovered by WGS). Nevertheless, the strong assignments
of the PIK3CA mutations to a cluster with average VAF near 50%
suggest that, despite the relatively high level of noise in the data,
they belong to the founding clone.

Longitudinal studies refine subclonal architecture and
reveal mechanisms of resistance
Tumors evolve in response to treatment, both through loss of
specific mutations and acquisition of new ones. Understanding this
process in the context of a tumor’s clonal architecture is critically
important in defining mechanisms of resistance and in informing
therapeutic decisions. To better understand mechanisms of
therapy resistance, we extended our method to accommodate
multiple samples and applied it (Fig. 3) to samples from a primary
AML tumor and post-treatment relapse occurring 26 months after
chemotherapy [5]. These primary and relapse tumors were
initially sequenced to depths of 26.7x and 31.5x, respectively,
with subsequent capture validation providing deep read counts for
all discovered variants (median depth: 753x). All variants were
analyzed, as no CNAs are present in either sample.
Analysis of the primary tumor sample in isolation (Fig. 3c)
suggests a simple organization consisting of a single subclone and a
founding clone containing an IDH2 R140L mutation. Mutations
in this residue may play a role in oncogenesis, given their
recurrence in AML [51] and resulting neomorphic enzymatic
activity [52]. Hence, this clonal mutation is an attractive target for
small molecule inhibitors, such as those reactive against IDH2
R140Q [53]. However, simultaneous analysis of the relapse
genome further dissects the apparently homogeneous highestfrequency cluster harboring IDH2 R140L into three distinct
subpopulations of cells (Fig. 3a): one that is effectively eliminated
by chemotherapy (cluster three, average relapse VAF v 0:5% ), a
second diminished by treatment (cluster two, average relapse VAF

Bayesian modeling quantifies the (un)certainty of
mutation clonality
Using WES to both discover variants and obtain deep read
counts for defining VAFs may be an attractive, direct approach to
clonality analysis [10], as it avoids the additional time and expense
of WGS followed by targeted sequencing. However, while WES
data captures the coding variants likely driving disease progression,
their number may be insufficient to reliably infer clonal
architecture, particularly for cancers with relatively low somatic
mutation rates. To begin to address these considerations, we
applied SciClone to whole-exome sequenced breast [49] and
PLOS Computational Biology | www.ploscompbiol.org
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Figure 2. Overcoming uncertainty in sparse exome-sequencing data to determine clonal structure and mutation clonality. (a) Breast
cancer sample with well-defined clones. (b) Endometrial cancer sample with overlapping clusters. PIK3CA mutations are strongly associated with the
dominant clone (posterior probabilities w 93%), whereas the clonal context of an ATM mutation is more ambiguous (57.8%).
doi:10.1371/journal.pcbi.1003665.g002

can be reliably distinguished if they lie greater than ,7% away
from one another.
To ensure that the inferred number and composition of clones
were not overly sensitive to our computational method, we varied
both the number of initial clusters and the clustering approach
itself. Consensus clustering indicated that the (subjectively) correct
number of clusters (five) was inferred by the variational Bayesian
beta mixture modeling for a range of initial number of clusters
from six to 15 (data not shown). We next used SciClone to cluster
using a variational Bayesian binomial mixture model and a
previously-published [40,54] variational Bayesian Gaussian mixture model (see Text S1). Consensus clustering indicates that the
results are stable for the majority of variants as both the number of
initial clusters and the method (beta, binomial, or Gaussian) are
varied (Fig. 4c). The few variants that clustered differently between
methods (Fig. S2) were situated near cluster boundaries or between
clusters. A similar effect was seen when clustering the data with
PyClone (Table S1), though in this case variants along cluster
boundaries tended to coalesce into independent clusters (clusters
six and eight in Fig. S3): PyClone’s default hyperparameter
settings lead it to overdissect the founding clone. After increasing
the number of iterations from 10,000 (with a burn-in of 1,000
iterations) to 100,000 iterations (with a burn-in of 10,000
iterations), PyClone results were even more similar to those
obtained with SciClone, but the former still split the highest-VAF
cluster into two (data not shown). Despite these differences, the
results are largely consistent between SciClone and PyClone and
we have increased confidence in variants that are similarly
assigned by both approaches.

11.6%), and a third largely unaffected by treatment (cluster one,
average relapse VAF 41.3%). As further evidence of their high
degree of overlap in the tumor sample, their respective average
VAFs in the tumor are 42.7%, 43.1%, and 44.9%. The additional
resolution provided by the relapse sample distinguishes these
subpopulations to expose a more complex clonal architecture
(Fig. 3d) and indicates that the IDH2 R140L mutation in cluster
two is subclonal. Thus, targeting it therapeutically would be
unlikely to eradicate the founding clone. We do observe that the
subclonal mutations in cluster five were eliminated by treatment,
suggesting that it carried a lower proclivity for resistance than the
surviving clones.
Remarkably, there is a second, independent IDH2 mutation
(R140W) in the relapse sample. But, as above, defining its clonality
from this sample alone (Fig. 3b) is confounded by an inability to
associate its VAF (32.8%) unambiguously with either the founding
clone or a subclone. This uncertainty is resolved through
multidimensional analysis that incorporates the tumor sample
and places the mutation in cluster four. Mutations within this
cluster, including IDH2 (R140W), were either present in the
primary tumor below the level of detection or are new mutations,
possibly induced by cytotoxic chemotherapy [5]. In either case,
they are potential drivers of disease progression.
Given the clonal complexity of this sample, we next asked how
many variants were required to capture this complexity and
whether we were likely to have missed additional complexity. To
address these concerns, we randomly selected a subset of the
original variants and performed clustering. The number of clusters
inferred as a function of the number of variants analyzed is fairly
constant for w 200 variants (Fig. 4a), whereas it drops precipitously for v 100 variants. As sequencing detected a total number
of variants within the flat regime of this curve, we can be confident
that no subclones with a higher VAF than the most infrequent
cluster identified (average VAF ,12%) were missed. Further, this
suggests that ,200 variants would have been sufficient to reveal
this sample’s clonal architecture. To assess the sensitivity of our
approach in inferring the separation of clusters, we performed onedimensional analysis of VAFs from relapse sample clusters one and
two (Fig. 3) after varying their inter-cluster separation (Fig. 4b).
While the results are sample-dependent, they indicate that clusters
PLOS Computational Biology | www.ploscompbiol.org

Multiple biopsies reveal intratumoral heterogeneity and
impact of treatment
Spatial heterogeneity complicates the analysis of solid tumors, as
distinct regions of a tumor may harbor different subclonal
populations [9,13,16]. Assaying multiple regions of heterogeneous
tumors should assist in uncovering the full spectrum of mutations
and subclones present in a tumor and help identify the spatial
origins of subclones that give rise to therapy resistance. To
investigate this effect, we analyzed two pre-treatment biopsies from
the same breast tumor and added a temporal dimension by
5
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Figure 3. Refining subclonal architecture from longitudinal analysis of tumor/relapse pair in acute myeloid leukemia (AML). Twodimensional analysis of tumor/relapse sample (a) dissects clusters one and four, which overlap in the relapse sample (b), and one, two, and three,
which overlap in the tumor sample (c). Single-sample analyses (b and c) show histogram (rectangles) with posterior predictive densities. Several
genes recurrently mutated in AML [5] are highlighted. (d) Inferred schematic of clonal evolution from a single hematopoietic stem cell, showing
percentage of cells belonging to each clone (i.e., twice VAF for this nearly pure sample). Broken vertical white lines correspond to primary tumor
sample (before chemotherapy) and relapse subsequent to treatment.
doi:10.1371/journal.pcbi.1003665.g003

examining a single sample from the tumor collected 16 weeks after
aromatase-inhibitor (AI) therapy. Mutations in the three samples
had median coverage of 130.5x from deep capture sequencing.
Three-dimensional clustering with SciClone revealed five
distinct groups of mutations and a fairly low purity, resulting in
reduced VAFs in all samples (Fig. 5, Movie S1). Differences
between the two pre-treatment biopsies were captured in clusters
four and five, containing region-specific mutations. Cluster two
cannot be identified from pre-treatment tumor one alone, but the
second biopsy reveals it as a distinct subpopulation of cells with
higher VAF in the first biopsy (36.03% vs. 8.13%). The effect of AI
therapy is revealed by inclusion of the post-treatment sample, in
which clusters two and four are eliminated. These likely represent
AI-responsive subpopulations of cells, though additional spatial
heterogeneity leading to their apparent removal cannot be
discounted. Cluster five contains mutations specific to the second
biopsy; while some of the cells harboring them expanded in the
PLOS Computational Biology | www.ploscompbiol.org

post-treatment sample, others appear to have been eradicated
completely. The heterogeneity in response observed in this cluster
suggests that it actually encapsulates several distinct, but overlapping subclonal populations that occur at similar VAFs in the pretreatment biopsy and are difficult to separate without additional
data.
Application of PyClone to these data (Table S1, Fig. S4) reveals
several significant differences. While it infers two distinct clusters
from the heterogeneous cluster five, it also partitions variants in
the founding clone into two clusters. This separation is likely a
clustering artifact, since (1) the two clusters are merged when all of
the data (in copy-altered and -neutral regions) are clustered using
34,000 iterations (data not shown) and (2) the presence of two
large, independent clusters comprising * 70% of the cellular
population each is biologically unreasonable. The discordance
between methods suggests that the limited number of variants
affected require special attention.
6
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Figure 4. Determining stability of inferred subclones as a function (a) of number of variants, (b) of inter-cluster separation, and (c)
of clustering method from AML sample. (a) A fraction of the ,800 variants from Fig. 3 were randomly sampled and the resulting number of
clusters was inferred using beta mixture modeling. Error bars represent standard deviation (n~ 10). (b) Mutations from clusters one and two from the
AML relapse sample were used to assess the limits of cluster separability. As the distance between the two mutation groups was varied, the resulting
clusters were assessed for overlap (the fraction of the data within a single standard deviation of both clusters) and accuracy (the fraction of items that
were correctly assigned to a second cluster). (c) Consensus clustering of the AML data set (Fig. 3) for number of initial clusters varied from six to 15
and clustering method varied across beta, Gaussian, and binomial mixture models for a total of 30 runs. N | N consensus matrix holds all N variants
across both rows and columns and has been reordered so that variants belonging to the same cluster are adjacent to one another. Matrix entry i, j is
the fraction of runs in which variant i and j were co-clustered; entry 1, 1 corresponds to the top-left of the matrix heat map. The narrowest neutralcolored band corresponds to a single variant alternatively classified by Gaussian mixture modeling (Fig. S2a). The larger neutral-colored band
corresponds to variants alternatively classified as a sixth cluster by binomial mixture modeling (Fig. S2b).
doi:10.1371/journal.pcbi.1003665.g004

including the isolation of drug-sensitive clones and small subpopulations driving relapse. To leverage the increasingly commonplace and cost-effective opportunities to sequence multiple samples
from an individual, we developed SciClone, which scalably
analyzes large numbers of samples to provide an unbiased,
probabilistic dissection of a cancer’s clonal landscape. To do so,
SciClone employs variational Bayesian mixture modeling of beta,

Discussion
Clonal heterogeneity complicates both our understanding of the
biology of tumors and the design of effective treatment strategies.
While an individual tumor sample provides a glimpse of this
complexity, additional temporally or spatially distinct samples
allow higher resolution mapping of subclonal architecture,

Figure 5. Assessing intratumor spatial heterogeneity and treatment response with multiple biopsies. Three breast tumor samples from
a single individual were simultaneously analyzed: two spatially distinct samples from a primary tumor and one sample taken after aromatase-inhibitor
treatment. (a–c) Two-dimensional slices and (d) still frame of the full three-dimensional interactive plot.
doi:10.1371/journal.pcbi.1003665.g005
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frequency harboring the corresponding variant. Because of the
widespread availability of variants to serve as clonal markers and
the relative reliability of their bioinformatic analysis and quantification, our initial clonality analyses have focused on SNVs.
Nevertheless, other genomic events have been used to identify
clonal dynamics. For example, the alternate ‘‘waxing’’ and
‘‘waning’’ of subclonal CNAs has been observed in multiple
myeloma [17,33]. However, the analysis and discovery of CNAs
pose several challenges for clonality: (1) Cancer types may be
described hierarchically in terms of their propensity to elicit either
mutations or copy number changes [56]. For mutation-dominated
cancer types, such as the cytogenetically-normal AML analyzed
here, few CNA events may be available for analysis. The converse
does not apply: since SNVs accumulate with age [4], an
abundance of SNV clonal markers are expected in all malignant,
as well as in non-malignant, tissues. Given the density of SNVs,
clonality analyses that rely solely on them may well capture the full
clonal architecture, while missing specific (copy number) events of
pathogenic interest; clonality analyses relying solely on copy
number events are likely to miss both. (2) There is no digital
readout of CNAs, rather observed copy number reflects the
admixture of subclonal populations and is a (linear) combination of
the copy number state of each subclone, weighted by the fractional
subpopulation of the subclone. In principle, the correctness of the
analysis requires the simultaneous inference of this admixture and
the number of copies (0, 1, 2, 3, or greater) of each chromosomal
segment in each subclone. Though such an analysis would infer
the clonal hierarchy directly, rather than the clusters of variants
that serve to identify them as in a SNV-based analysis, inference in
the latter case is simplified since there are fewer mutational states
(presence or absence, at least of the vast majority of variants, which
are heterozygous) and the correctness of inferring one cluster is
independent of a second cluster.
For these reasons, we prefer to overlay CNA events on the
higher confidence copy-number neutral SNV VAFs. Incorporating such events is important: (1) to include SNVs from CNA
regions, which are especially likely to be involved in disease, and
(2) to ameliorate the loss of SNVs from copy-number neutral
regions occurring as the number of genomic regions perturbed by
CNA (in some sample) increases with the number of samples
analyzed. Accommodating these events may be accomplished: (1)
by determining the fractional population harboring the event (as in
Fig. S1) or (2) by adjusting a SNV’s VAF based on it’s inferred
copy number states across subclonal populations. One approach to
the latter involves inferring copy number states from the B-allele
frequencies of germline SNPs (e.g., using ASCAT [34] or
APOLLOH [39]) and phasing these to somatic variants (e.g., by
detecting a single sequencing read spanning both) to impute
subclone-specific copy numbers to each variant [6]. After adjusting
the SNV VAFs, they could be clustered by SciClone in a manner
completely analogous to the analysis of unadjusted VAFs (using
the beta or Gaussian mixture model approaches). We are currently
pursuing this approach.
MCMC techniques, such as PyClone [11,30], offer an
alternative approach to clustering variants. However, our comparisons of SciClone and PyClone (Table S1) reinforce the
computational inefficiencies of MCMC approaches relative to
variational Bayesian techniques [40] and show that SciClone is
between one and two orders of magnitude faster. SciClone inherits
the simple variational Bayesian (computational) convergence
condition of monitoring monotonic changes in a lower bound
(see Text S1). While this approach may converge to a local
extremum, more subtlety is required to ensure the (theoretical)
asymptotic convergence to the global extremum guaranteed by

binomial, and Gaussian distributions. Each of these may have
advantages (see Text S1) in certain situations, though our tests
suggest that the beta mixture model works best in practice. We
have previously used related techniques in analyzing FACS data
[55] and expect them to be of general interest to those requiring
methods that automatically and efficiently infer the number of
clusters from high-dimensional biological data.
Application of SciClone to primary and relapse AML tumors
identified subclonal populations with dramatically divergent
response to conventional therapy. Such analyses are the first step
towards inferring driver mutations responsible for both resistance
to therapy and clonal expansion following treatment. Insight into
the spatial origins of treatment response was provided by analysis
of three samples from a breast tumor, two of which were obtained
from distinct regions of a single tumor at the same time point.
The AML and breast cancer cases highlight an inherent
limitation of bulk sequencing of tumor cells: subclonal populations
cannot be distinguished if they occur at similar frequencies. Singlecell sequencing may eventually offer a solution, but will require
dramatic improvements in fidelity and throughput. Using
currently available data, we demonstrated that temporally or
spatially distinct samples from the same tumor can be used to tease
apart these overlapping subclones. This is demonstrated in AML,
where the apparent founding clone in the primary tumor is
dissected into two additional subclones by incorporating the
relapse sample. The breast cancer samples exhibit two-fold
complexity. As in the AML primary tumor, a cryptic subclone is
revealed in the pre-treatment breast tumor when multiple samples
are considered; in this case, from two spatially-isolated biopsies.
Additionally, each pre-treatment sample exhibits a clone not
detected in the other. This suggests that manipulation of the
patient’s tumor-derived cells (e.g., passage within culture or as
mouse xenografts) may be a viable method for identifying
additional subclones and predicting those with differential
responses to therapy.
Our analysis of exome-sequenced cases showed that SciClone
can be useful on samples with as few as 29 SNVs (Fig. 2a), but our
simulations (Fig. 4a) showed that in more complex cases, such as
the AML tumor/relapse pair, establishing subclonal boundaries
may require two hundred or more variants and that subclones be
separated by VAFs of ,7% or more (Fig. 4b). This downsampling
approach may be applied to any data set to establish a baseline
sensitivity. Cases with poorly defined cluster boundaries (e.g., due
to a paucity of mutations), such as the endometrial case (Fig. 2b),
benefit from SciClone’s probabilistic formalism. In particular, by
assigning an ATM mutation similar probability of belonging to the
founding clone and a subclone, SciClone reflected the lack of
certainty inherent in the data and indicated that their sparsity may
poorly characterize the tumor’s clonal diversity. The sensitivity of
any clustering method in dissecting clonal boundaries is dependent
on cluster overlap, which we have characterized via the
‘‘uncertainty’’ of their probabilistic assignments (Refs. 45 and 46
and Materials and Methods). An additional, qualitative means of
detecting high-confidence variant/cluster assignments involves
taking the consensus, or intersection, across clustering methods
(Fig. 4c). Confidence in detecting all major subclones increases
with the number of variants, including passenger mutations more
likely to be missed by exome sequencing. Thus, WGS followed by
deep validation sequencing is most likely to capture the full
spectrum of mutations and yield high-quality characterization of
subclonal entities.
Next-generation sequencing of variants within copy-number
neutral regions of autosomal chromosomes leads to a straightforward interpretation of the inferred VAFs as half the cellular
PLOS Computational Biology | www.ploscompbiol.org
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marginal probability p( znk ~ 1) that a VAF belongs to component k is given by its mixing coefficient p k ,

MCMC, e.g., monitoring variance within a Markov chain relative
to variance between independent Markov chains [41]. PyClone
provides no direct facilities to monitor convergence. Regardless,
the theoretical convergence properties of MCMC seem unjustified
given the involved computational overhead for a clustering
application, such as clonality detection, where error estimates of
the parameters are of marginal interest.
SciClone has already contributed to the understanding of
biological mechanisms underlying cancer and has the potential for
increased utility with the advent of clinical sequencing. Towards
this end, we are developing methods that cross-reference the clonal
status of specific mutations with databases of targeted therapeutics.
As an example, the Drug-Gene Interaction Database [57]
identifies three genes in the AML sample as as potentially
druggable: (DRD2, KCNQ2, and P2RY2). The fact that each of
these mutations lies in a subclone complicates their interpretation,
and suggests that careful study is needed to understand how
specific subclonal populations respond to different therapeutics.
While clinical decisions of which (sub)clones to target and how
remain controversial, it is clear that making these decisions will
require accurate assessment of clonal architecture using tools such
as SciClone.

p(znk ~1)~pk ,
subject to the probabilistic constraints
0ƒpk ƒ1 ,

K
X

pk ~1 :

k~1

Given the 1-of-K representation of zn , this may be written as
K

p(zn Dp)~ P pk znk :
k~1

ð2Þ

Similarly, the conditional distribution p( f n D zn , U, V ) that a
VAF f n arises from the mixture may be written

Materials and Methods
Variational Bayesian mixture modeling of beta
distributions

K

p(f n Dzn , U, V )~ P Beta(f n ; uk ,vk )znk
k~1

ð3Þ

var

A VAF f is defined with respect to the number of reads, x ,
supporting the variant allele and the number of reads, xref ,
supporting the reference (or non-major-variant, in the case of
xvar
. Our previous method
multiple variants) allele: f ~ var
x z xref
[14] considered variants in a single sample and modeled the
probability of a VAF f belonging to cluster k as
Beta(f ; uk ,vk )~

in terms of the shape parameter vectors uk and vk of the kth beta
component, with aggregate parameters U : f uk g and
V : f uk g .
To accommodate binomial and Gaussian mixture models in
addition to the beta mixture model, we introduce abstract notation
used below to define quantities (e.g., p-values) independently of the
concrete representation of likelihoods and posterior distributions.
We begin by defining abstract parameters W , which differ
according to the model, i.e., beta, binomial, or Gaussian. For
example,
p( f n D zn , W beta ) : p( f n D zn , U, V ) ,
with
W beta : f U, V g . Further, while the Gaussian mixture model
is also a function of VAFs f, the binomial mixture model is defined
with respect to the variant and reference count vectors, xvar and
xref , respectively. To abstract away these details, we use the
notation x to denote the VAFs f of a beta or Gaussian mixture
model or the counts xvar and xref of a binomial mixture model,
when convenient. In particular, p( x n D zn , W beta ) :
p( f n D zn , W beta ) : p( f n D zn , U, V ) , while p( x n D W beta
):
k
p( f n D uk , vk ) , with W beta
: f uk , vk g .
k
Eqns. (2) and (3) extended across the entire set F : f f n g of
VAFs (or, more abstractly, X : f x n g of data) and their
associated latent variables z : f zn g are combined to express the
complete-data (i.e., including the latent variables) likelihood

C(uk zvk ) u {1
f k ð1{f Þvk {1
C(uk )C(vk )

where C ( : ) is the gamma function. Here, we extend this to the
case with S§ 1 samples by defining the S-vector
f : ( f1 , f2 , . . . , fS ) , whose sth component, fs , is the VAF of
that variant in the sth sample. We make the assumption that,
within a cluster, the VAFs are independent across samples, so that
the cluster may simply be modeled as
S

p(fDuk ,vk )~Beta(f; uk ,vk )~ P Beta(fs ; uks ,vks ) ,
s~1

ð1Þ

where uk and vk are the S-vectors whose sth components are uks
and vks , respectively. This implies only that within a cluster there
is no correlation between samples. The validity of this
assumption is indicated by the visually-observed orthogonality
of the VAF principal component axes to the coordinate (i.e.,
sample) axes. We have rarely, if ever, seen evidence for such
intra-cluster correlation. Nevertheless, this assumption may be
relaxed through use of a mixture of multivariate Gaussian
distributions (see Text S1), each of which has a full-rank
covariance matrix.
In considering a mixture of K (multi-dimensional) beta
components [Eq. (1)], we introduce a K-dimensional latent (or
unobserved) binary random variable zn indicating whether VAF f n
does (znk ~ 1) or does not (znk ~ 0) belong to component k and
P
satisfying a 1-of-K representation in which K
k~ 1 znk ~ 1. The
PLOS Computational Biology | www.ploscompbiol.org

N

K

p(X,ZDp,Wbeta ):p(F ,ZDp, U, V )~P P ½pk Beta(f n ; uk ,vk )znk ,ð4Þ
n~1 k~1

which may be summed over zn to give the incomplete likelihood
N

p(F Dp, U, V )~ P

n~1

K
X

pk Beta(f n ; uk ,vk ) :

k~1

These equations could be used to fit the beta parameters using
expectation maximization (EM) or Markov chain Monte Carlo
(MCMC) techniques.
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We instead use a previously described [43,44] variational
Bayesian approach [40,42,54,58,59] to modeling a mixture of beta
distributions. The general variational Bayesian theory and its
application to mixture modeling are described in depth in several
excellent references [40,42,54,58,59]. To establish consistent
notation, we provide an abridged, but self-contained, introduction
to this general theory and to its application to Gaussian
[40,54,58,59] and binomial mixture models in Text S1. Here,
we summarize its application to beta mixture models to provide
sufficient context for its use in and extension for clonality analysis.
For full details of this derivation, the reader is referred to the
original references [43,44].
Variational Bayesian beta mixture modeling approximates the
posterior distribution, p( Z, p , W beta D X ) : p( Z, p , U, V
D F ) , over the model parameters p , U , and V and the latent
variables Z with a distribution q( Z, p , W beta ) :
q( Z, p , U, V ) . The form of this approximate distribution is a
consequence of choice of prior distribution, whose product with
the likelihood [Eq. (4)] defines the posterior p( Z, p , U, V D F )
according to Bayes’ theorem, and of the mild and standard [40]
assumption that the latent variables Z factorize from the model
parameters, i.e., q( Z, p , U, V ) ~ q( Z) q( p , U, V ) . This further simplifies, without assumption, to q( Z, p , W beta )
:q( Z, p , U, V ) ~ q( Z) q( p ) q( U, V ) : q ( Z) q( p ) q
( W beta ) . Finally, the authors assume the U and V variables are
independent and factorize to ultimately give q ( Z, p , U, V )~
q( Z) q( p ) Pk, s q( uks ) q( vks ) .
Ma and Leijon used four synthetic one-dimensional data sets
(Fig. 4 of Ref. 43), including two with highly overlapping beta
distributions, to demonstrate the high accuracy of this method
despite its assumption that the parameters of the beta distribution
are independent. Fan et al. [44] additionally analyzed six threedimensional data sets and similarly found that accuracy was not
adversely effected by this factorization approximation (Table I of
Ref. 44). Our own extensive simulation results further support
these findings. We generated data sets by sampling a mixture of
beta distributions in one, two, or three dimensions and having
between two and five clusters (100 data sets for each dimensionality/number of clusters pair). Fig. S5 shows the concordance (i.e.,
fraction of correctly assigned items) between the clustered and
known results for each simulated data set. The average concordance is 0:861, 0:985, and 0:999 in one, two, and three
dimensions, respectively. Performance increases with dimensionality as the clusters become increasingly separated. This sparsity
may be quantified by the minimum cluster self-overlap (see below).
Data sets having a relatively small minimum cluster self-overlap
have a relatively large overlap between clusters, which leads to
uncertainty and degrading performance.
The prior distributions are generally selected to be conjugate to
the likelihood for analytic convenience (e.g., see the derivations of
the variational Bayesian Gaussian and binomial mixture models in
Text S1). While a conjugate prior to the beta likelihood is formally
available, its use would lead to an analytically intractable
integration [43]. Therefore, Ma and Leijon [43] instead propose
use of the following prior distribution

Gam(u; m,a)~

K

D (p; c)~C(c) P pk ck {1
k~1

over proportions p , with the normalizing constant C( c)
C(c)~

0
ks

) and Gam( vks ; n

^c:
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,b

0
ks

K
X

ck :

k~1

The parameters of the approximate posterior distribution are
now determined by iteratively minimizing the Kullback-Leibler
divergence, a measure of the difference, between it and the
posterior distribution, following the general prescription of
variational Bayesian inference (see Text S1). The authors make
a non-linear approximation to an expectation value arising during
the iterative procedure so that the resulting, approximate posterior
distribution has the form of a gamma distribution, despite the fact
that the above gamma prior distribution is not conjugate to the
beta likelihood. Significantly, the authors show that this additional
approximation can be used to minimize the original, desired
Kullback-Leibler divergence between the posterior distribution
and the approximate, non-gamma posterior distribution. This
results in the approximate posterior distribution
K

S

q(p,Wbeta ):q(p) P P q(uks )q(vks )
k~1 s~1

ð6Þ
K
S
~D (p; c) P P G am(uks ; mks ,aks )G
Gam(vks ; nks ,bks ) ,
k~1 s~1

where ck , m ks , a ks , n ks , and b ks are defined in Eqns. 47–51,
respectively, of Ref. 43. These parameters are updated from the
corresponding initial hyperparameter values c0k , m 0ks , a 0ks , n 0ks ,
and b 0ks as in a traditional EM iterative algorithm. It will also be
convenient to define the posterior density with respect to the kth
component
S

q(Wbeta
k ): P q(uks )q(vks ) :
s~1

ð7Þ

Probabilistic and hard cluster assignments
Variational Bayesian mixture models provide probabilistic
assignments of variant x n (i.e., a VAF f n for beta or Gaussian
mixture models or variant counts xvar
for a binomial mixture
n
model) to cluster k according to the posterior probabilities
p( znk ~
P1D x n ) : rnk . The rnk act as ‘‘responsibilities’’ and
satisfy k rnk ~ 1: In the case of the beta mixture model, the rnk
are defined by Eqns. 31 and 32 of Ref. 43. A more general
derivation is provided in Text S1, along with specific calculations
for binomial and Gaussian mixture models.

ð5Þ

0
ks

C(^c)
Pk C(ck )

and

p(p)~ D (p; c0 )
where Gam( uks ; m 0ks , a
gamma distributions

m, a [ Rz ,

and D ( p ; c0 ) is the Dirichlet distribution

p(uks )~Gam(uks ; m0ks ,a0ks )
p(vks )~Gam(vks ; n0ks ,b0ks )

am m{1 {au
u e
C(m)

) are
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For visualization purposes, for example, we occasionally
transform these probabilistic assignments into hard assignments,
which assign X n to one and only one cluster k according to

Prior initialization
We choose hyperparameters resulting in prior distributions
sufficiently broad to ensure that the number of clusters and their
posterior parameterization are determined primarily from the
data rather than from prior assumptions. In particular, following
Ma and Leijon [43], we choose c0k ~ 0:001 for all k. We also
choose a 0ks ~ b 0ks ~ 0:005 and m 0ks ~ n 0ks ~ 1 for all k.
Given the latter choice, the gamma distributions
Gam( uks ; m 0ks ~ 1, a 0ks ) and Gam( vks ; n 0ks ~ 1, b 0ks ) collapse to exponential distributions. The resulting variances of these

2
, are large given our
distributions, e.g., Var½uks ~ 1=a 0ks
choice of hyperparameters and hence provide a broad prior.
We initialize the rnk according to the hard assignments
computed by k-means (provided in the R stats package and
using default parameters, except with nstart~ 1000 and
centers~ 10). We initialize the parameters m ks , n ks , and b ks
to their respective hyperparameter values m 0ks , n 0ks , and b 0ks .
Finally, we initialize the a ks such that the expected means of the
cluster centers, 
uks =( 
uks z vks ) , with 
uks ~ E½uks ~ m 0ks =a 0ks
0
0
and vks ~ E½vks ~ n ks =b ks , are set to the values returned by
k-means. We then perform the variational E step (i.e., calculate
the expectations immediately following Eq. 51 of Ref. 43) without
updating the rnk , followed by the variational M step to update the
parameters m ks , n ks , n ks , b ks , and ck (via Eqns. 47–51 of Ref.
43). For the AML28 data set, this initialization results in the
clusters shown in Fig. S6a. Initialization is followed by iteratively
applying the variational E step (including updating the rnk ) and M
step. To avoid undefined behavior in evaluating the beta
distribution, we shift VAFs at zero or one by d or { d ,
respectively, with d equal to machine precision.

k~arg maxp(znk’ ~1Dx n ) :
k’

Posterior predictive density
The posterior predictive density gives the probability of a new
(i.e., unobserved) variant, ^x , given the observed data X
p(^xDX )~

Xð

p(^xD^z,W)p(^zDp)p(p,WDX )dpdW

^z

and all possible assignments ^z of that variant to a cluster.
Evaluating the sum over ^z, making use of Eq. (2), gives

p(^xDX )~

K ð
X

pk p(^xDWk )p(p,WDX )dpdW :

k~1

We next approximate the true posterior distribution,
p( p , W D X ) , with the variational approximation q( p , W ) to give

p(^xDX )&

K ð
X

pk p(^xDWk )q(p,W)dpdW :

k~1

Since for all mixture models considered in this manuscript
q( p , W ) ~ q( p ) q( W ) , with q( p ) ~ D( p ; c) and
Ep ½pk ~

ð

Cluster pruning and outlier detection
Variational Bayesian mixture modeling generally discards
clusters that do not contribute to the model, as determined by
the data and strength of the prior distribution. Specifically,
following convergence of the variational iteration and hard
assignments of variants to clusters, we remove any clusters having
less than the larger of three variants or 0.5% of N, the total
number of variants, assigned to them, a condition similar to our
earlier approach [14]. If clusters are removed, the algorithm is
again executed until convergence. For the beta mixture model,
convergence is achieved when the absolute difference between all
p k across consecutive iterations is less than 10 { 4 . This
condition differs slightly for binomial and Gaussian mixture
models (see Text S1). The minimum cluster membership is
motivated by the requirement of needing at least two proportions
to fix the two degrees of freedom, uk and vk , of a beta distribution.
More intuitively, clustering is effectively a separation of intra- and
inter-cluster distances. Defining an intra-cluster distance requires
at least two items be assigned to that cluster.
To be conservative in our assessment of subclonality, we
require clusters be well separated. Previously [14], we used a
condition on overlapping cluster standard error of the means to
detect and remove overlapping clusters. Here, we instead adopt a
quantitative notion of cluster overlap [45,46], in which overlap
between clusters k and k’ results in uncertain assignments of
some variants, causing them to have appreciable rnkPand rnk’ .
This in reflected in a large relative (to the ‘‘size’’,
n rnk , of
cluster k) cluster overlap

ck
pk q(p)dp~ ,
^c

this evaluates to

p(^xDX )&

ð
K
X
ck
k~1

^c

p(^xDWk )q(W)dW :

ð8Þ

Ma and Leijon [43] assumed that q( W ) & d ( W { W  ) ,
where d ( : ) is the Dirac delta function and W  are the
converged parameter values, i.e., that the posterior distribution
has negligible probability when any of the parameters differ from
their converged values. In this case,

p(^xDX )&

K
X
ck
k~1

^c

p(^xDWk ) ,

which may be efficiently evaluated. We instead use Eq. (8), which
avoids any assumption on the approximate posterior distribution.
In the case of binomial and Gaussian mixture models, Eq. (8) may
be evaluated analytically. In the case of a beta mixture model, for
which p( ^x D W k ) is given by Eq. (1) and q( W ) is given by Eq.
(7), we instead resort to numerical integration, evaluating data
sampled from Eq. (7) via Eq. (1).
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and involves integrating the mean, u=( uz v) , with respect to the
posterior distribution.
Several iterations of the AML28 data set following the k-means
initialization (above and Fig. S6a) are shown in Figs S6b and c,
with the complete run shown in Movie S2.

P
n rnk rnk’
U k,k’ : P
:
n rnk
Minimizing this quantity for all k’ = k is equivalent to
maximizing the ‘‘self-overlap’’ of cluster k with itself,

Variant detection and copy number calling
Sequencing, alignment, and variant calling were performed as
previously described [5]. Somatic copy number events were detected
using copyCat (http://github.com/chrisamiller/copycat/). Copynumber neutral LOH was detected using VarScan 2 [38] and
filtered to retain regions with 95% LOH and at least 10 sites.

P
X
n rnk rnk
 k :1{
U
U k,k’ ~ P
,
n rnk
k’=k
 k ƒ 1. Hence, we remove any cluster
which satisfies, N { 1 ƒ U
 k less than a threshold U . Overlap between
having a U
(independent) clusters will be more likely in lower dimensional
problems; hence, to determine a dimensionality-dependent U we
clustered simulated data sets by sampling a mixture of beta
distributions in one, two, or three dimensions and having
between two and five clusters. Average concordance (across data
sets of a given dimensionality) between the clustered and known
results (in terms of fraction of correctly assigned items) was stable
for a wide range of U within each dimension: U in the range of
0:5 to 0:8 achieved the maximal concordance (of 0:86) in one
dimension, U in the range of 0:83 to 0:96 achieved a
concordance of 0:96 { 0:97 in two dimensions, and U in the
range of 0:84 to 0:99 achieved a concordance greater than or
equal to 0:97 in three dimensions. Intuitively, we anticipate that
the probability of clusters overlapping scales inversely with the
number of dimensions. Hence, we define U S for an S1=S
dimensional problem as U S : U 1 , where U 1 ~ 0:70 was
selected so that U S passes through the above optimal regions
defined by the simulation. Namely, U 2 & 0:84 and U 3 & 0:89.
Results for these settings of U S across all simulated data sets are
shown in Fig. S5.
We detect outliers using a more formal approach than our
previous method [14], by calculating the p-value of a variant with
the respect to the cluster to which it has been assigned (via a hard
assignment). If the probability of the variant belonging to that
cluster is less than pmin , the variant is removed from the analysis.
The default used in this manuscript is pmin ~ 10 { 2 (which is not
corrected for multiple testing). The p-value of a variant x n is
calculated with respect to the predictive posterior distribution [Eq.
(8)] as
ð

PyClone
PyClone version 0.12.3 was downloaded from http://compbio.
bccrc.ca/software/pyclone/. VarScan 2-detected regions of LOH
were excluded from analysis. Copy number events detected by
copyCat were quantized and passed to PyClone as major_cn, with
minor_cn set to zero; additionally, PyClone was run with ––
var_prior total_copy_number, since allele-specific copy number
calls were not provided. PyClone clustering used the beta-binomial
mixture model. Initially, we attempted to cluster using 10,000
iterations and 1,000 burn-in iterations, as suggested by the authors
(Ref. 30 and https://bitbucket.org/aroth85/pyclone/wiki/
Tutorial). However, these parameters yielded discordant clusterings
across three runs. Therefore, we varied the number of total
iterations (and additionally varied the number of burn-in iterations
to be 10% of the total iterations) and for each configuration assessed
concordance across three independent runs. The authors have
suggested similar approaches based on visual inspection of
convergence across randomly-initialized runs [30]. We choose the
number of iterations at which the concordance across the three runs
stabilized. These are given in Table S1. Concordance was evaluated
for each of the three pairs and was calculated as the maximal
fraction of items assigned to the same cluster across permutations of
the cluster labels of one of the two runs being compared.

THetA
THetA version 0.51 was downloaded from http://compbio.cs.
brown.edu/projects/theta/. After failing to successfully run the
program on the complete set of copy number events in the MM
sample, we selected seven copy number regions, representing
neutral, amplified, and subclonally deleted chromosomes, and ran
THetA as described in the manual (parameters: –n 3 –k 4 –m 0.10
––NUM_PROCESSES 2). The resulting population frequencies
and copy number assignments were used to infer the VAF at which a
SNV in that region would appear. These sites were added to the list
of SNV inputs to SciClone and clustered with default parameters.

h½p(x n DX ){p(xDX )p(xDX )dx

where h ( x) is the Heaviside step function with h ( x) ~ 1 for
xw 0 and h ( x) ~ 0 for xv 0. In the case of beta mixture
models, this integral is evaluated numerically by sampling from the
predictive posterior distribution and then evaluating sampled
variants with that distribution, which again involves numerical
integration. For computational efficiency, we only calculate this
integral for variants likely to be outliers, which we heuristically
define as variants whose VAF f in each sample s lies outside of the
pﬃﬃﬃ
narrowest interval containing erf( 0:75= 2 ) & 0:55 of the
fluctuation in the mean of cluster k. This interval ( loks , hiks ) is
determined as the narrowest such interval satisfying

Supporting Information
Figure S1 Integration of copy number-derived subclonal information from THetA. THetA was used to detect
clonal and subclonal copy-number events in a multiple myeloma
sample, then converted to pseudo-VAFs and co-clustered with
SNV data using SciClone. CN-derived points are highlighted in
yellow. The leftmost two CN events are single points and the
rightmost point consists of six overlapping points.
(TIF)
Figure S2 Detecting ambiguous or low-confidence associations between a variant and clone from inconsistent assignments across clustering methods. Clonal
dissection of AML sample (Fig. 3) based on (a) Gaussian or (b)

0:55~
ð? ð?
ð hi
ks

f ~loks

u~0



u
d f{
Gam(v; nks ,bks )df dudv
G am(u; mks ,aks )G
uzv
v~0
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binomial variational mixture modeling. Beta mixture modeling
(Fig. 3) differs from Gaussian mixture modeling in the single
variant highlighted by arrow in (a) and from binomial mixture
modeling in the separation of cluster two from cluster one in (b).
(TIF)

Figure S6 Converging to clustering solution using
variational Bayesian beta mixture model. k-means initialization (A) of AML sample (Fig. 3) and results following second (B)
and fourth steps (of six) in iteration (C).
(TIF)

Figure S3 Confirming subclonal AML populations using
an independent method. PyClone largely recapitulates subclonal architecture inferred by SciClone (Fig. 3), though the
parameter settings used here (default hyperparameters to betabinomial mixture, with 10,000 iterations, and a burn-in of 1,000
iterations) overdissect the founding clone.
(TIF)

Movie S1 Interactive, three-dimensional clustering of
three breast tumor samples from a single individual (see
Fig. 5d).
(MP4)
Movie S2 Movie of convergence of AML sample clustering (see Fig. 3 and Fig. S4).
(SWF)

Figure S4 Confirming subclonal breast tumor populations using an independent method. PyClone clustering of
variants in copy-number neutral regions is similar to that obtained
by SciClone (Fig. 5), though the former partitions the variants
spread along the pre-treatment tumor 2 axis (clusters 1 and 2), as
well as those belonging to the founding clone (clusters 7 and 9).
Subpanels (a–c) correspond to two-dimensional slices in Fig. 5 of
three breast tumor samples (two spatially distinct samples from a
primary tumor and one sample taken after aromatase-inhibitor
treatment).
(TIF)

Table S1 Execution time of SciClone (Variational
Bayes) and PyClone (MCMC).
(PDF)
Text S1 Supplemental methods and discussion.

(PDF)
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Figure S5 Assessing concordance between known and
clustered results. Beta mixtures having two to six components
were sampled in (a) one, (b) two, or (c) dimensions and clustered.
Concordance is the fraction of data points correctly clustered; the
highest concordance resulting from a permutation of the cluster
labels is reported. Reported self-overlap is the minimum reported
over any cluster, i.e., min k U k . Self-overlap is shifted by 0.1 in
the plots for visual purposes to avoid obscuring concordance.
(TIF)
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